Table 1. Characteristics of cohort studies included in PCP risk meta-analysis for patients with and without rituximab.
| Author(year) | Country | Disease | Cohort size | Diagnostic method | Chemo-regimen | Chemo-cycle (day) | Onset time of PCP | Outcome | |
|---|---|---|---|---|---|---|---|---|---|
| Cured | died | ||||||||
| Ennishi (2008) | Japan | NHL | 195 | PCR | (R-)CHOP | NG | 60–120d | 2 | 0 |
| Huang (2011) | China | DLBCL | 529 | microscopy | (R-)CHOP | 21 | 4(1–7)cycle | NG | |
| Kato (2011) | Japan | NHL | 103 | microscopy | (R-)CHOP | NG | 212d | 1 | 0 |
| Katsuya (2009) | Japan | NHL | 188 | PCR/β-glucan | (R-)CHOP | 21/14 | 4,6,7cycle | 2 | 1 |
| Kolstad a (2007) | Norway | NHL | 71 | PCR | (R-)CHOEP | 14 | NG | 6 | 0 |
| Kolstad b (2007) | Norway | NHL | 417 | PCR | (R-)CHOP | 21 | NG | 2 | 0 |
| Kolstad c (2007) | Norway | NHL | 81 | PCR | (R-)CHOP | 14 | NG | 2 | 0 |
| Kurokawa (2010) | Japan | NHL | 235 | PCR/β-glucan | (R-)CHOP | NG | 2,3,4,4,5cycle | 4 | 1 |
| Lim (2010) | Korea | NHL | 100 | DFA | (R-)CHOP | 21 | 27–117d | NG | |
DFA: direct fluorescent antibody assay; DLBCL: diffuse large B cell lymphoma; ND: not do; NG: not given; NHL: non-Hodgkin’s lymphoma; NOS: Newcastle-Ottawa quality assessment scale; PCR: polymerase chain reaction; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOEP: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide